Fibrozumab: A bispecific antibody for cancer and fibrosis
Targeting:
Drug-Resistant Cancer Cells
Activated Fibroblasts
Angiogenic Endothelial Cells
Same mechanism, additional therapeutic opportunities
Pancreatic cancer stroma
Disassembles CAF-built fibrotic matrix in vitro and in vivo; reduces stromal stiffness and reverses fibrosis hallmarks.
Lung fibrosis
Blocks fibronectin and collagen assembly by fibroblasts from IPF patients while sparing physiological matrix in healthy fibroblasts.
Liver fibrosis
Reduces fibrotic gene expression in human liver spheroids stimulated with a fibrotic cocktail; consistent with hepatic stellate cell biology.
How can Fibrozumab target cancer and fibrosis?
Blocking the same targets on multiple cell types involved in drug resistance, cancer progression, and fibrosis:
Adjuvant PDAC after curative-intent resection.
An essential combination partner for resistance-prone targeted therapy.
To disrupt tumor fibrosis by targeting cancer-associated fibroblast production of fibronectin.
To suppress tumor-associated angiogenesis.